HRP20231196T1 - Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba - Google Patents

Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba Download PDF

Info

Publication number
HRP20231196T1
HRP20231196T1 HRP20231196TT HRP20231196T HRP20231196T1 HR P20231196 T1 HRP20231196 T1 HR P20231196T1 HR P20231196T T HRP20231196T T HR P20231196TT HR P20231196 T HRP20231196 T HR P20231196T HR P20231196 T1 HRP20231196 T1 HR P20231196T1
Authority
HR
Croatia
Prior art keywords
antigen
antibody
seq
binding fragment
sequence
Prior art date
Application number
HRP20231196TT
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of HRP20231196T1 publication Critical patent/HRP20231196T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • G01N2333/183Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (13)

1. Izolirano protutijelo ili njegov fragment koji se veže na antigen, koje se specifično veže na epitop Zika virusa i neutralizira infekciju Zika virusom, pri čemu protutijelo ili njegov fragment koji se veže na antigen sadrži aminokiselinske sekvence CDRH1, CDRH2, i CDRH3 i aminokiselinske sekvence CDRL1, CDRL2, i CDRL3 (i) prema SEQ ID NOs: 1 - 5 i 7; (ii) prema SEQ ID NOs: 1 - 4 i 6 - 7; (iii) prema SEQ ID NOs: 19 - 23 i 25; (iv) prema SEQ ID NOs: 19-22 i 24 - 25; (v) prema SEQ ID NOs: 37 - 41 i 43; (vi) prema SEQ ID NOs: 37 - 40 i 42 - 43; (vii) prema SEQ ID NOs: 73 - 77 i 79; ili (viii) prema SEQ ID NOs: 73 - 76 i 78 - 79.
2. Protutijelo, ili njegov fragment koji se veže na antigen, prema zahtjevu 1, naznačeno time što protutijelo, ili njegov fragment koji se veže na antigen, sadrži Fc ostatak; poželjno protutijelo, ili njegov fragment koji se veže na antigen, sadrži mutaciju u Fc ostatku, pri čemu navedena mutacija smanjuje vezanje protutijela na Fc receptor; poželjnije protutijelo, ili njegov fragment koji se veže na antigen, sadrži mutaciju CH2 L4A, mutaciju CH2 L5A, ili obje.
3. Protutijelo, ili njegov fragment koji se veže na antigen, prema zahtjevu 1 ili 2, naznačeno time što protutijelo, ili njegov fragment koji se veže na antigen, sadrži (i) aminokiselinsku sekvencu varijabilne regije teškog lanca (VH) prema SEQ ID NO: 8 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence i/ili aminokiselinsku sekvencu varijabilne regije lakog lanca (VL) prema SEQ ID NO: 9 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence; (ii) aminokiselinsku sekvencu varijabilne regije teškog lanca (VH) prema SEQ ID NO: 26 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence i/ili aminokiselinsku sekvencu varijabilne regije lakog lanca (VL) prema SEQ ID NO: 27 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence; (iii) aminokiselinsku sekvencu varijabilne regije teškog lanca (VH) prema SEQ ID NO: 44 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence i/ili aminokiselinsku sekvencu varijabilne regije lakog lanca (VL) prema SEQ ID NO: 45 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence; ili (iv) aminokiselinsku sekvencu varijabilne regije teškog lanca (VH) prema SEQ ID NO: 80 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence i/ili aminokiselinsku sekvencu varijabilne regije lakog lanca (VL) prema SEQ ID NO: 81 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence.
4. Protutijelo, ili njegov fragment koji se veže na antigen, prema bilo kojem od prethodnih zahtjeva naznačeno time što se koristi kao lijek.
5. Molekula nukleinske kiseline naznačena time što sadrži polinukleotid koji kodira protutijelo, ili njegov fragment koji veže antigen, prema bilo kojem od prethodnih zahtjeva.
6. Vektor naznačen time što sadrži molekulu nukleinske kiseline prema zahtjevu 5.
7. Stanica koja eksprimira protutijelo, ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3; ili koja sadrži vektor prema zahtjevu 6.
8. Farmaceutski pripravak koji sadrži protutijelo, ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3, nukleinsku kiselinu prema zahtjevu 5, vektor prema zahtjevu 6 i/ili stanicu prema zahtjevu 7; i, izborno, farmaceutski prihvatljivu pomoćnu tvar, sredstvo za razrjeđivanje ili nosač.
9. Protutijelo, ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3, nukleinska kiselina prema zahtjevu 5, vektor prema zahtjevu 6, stanica prema zahtjevu 7, ili farmaceutski pripravak prema zahtjevu 8 za upotrebu u prevenciji ili liječenju infekcije Zika virusom.
10. Protutijelo, ili njegov fragment koji se veže na antigen, nukleinska kiselina, vektor, stanica ili farmaceutski pripravak za upotrebu prema zahtjevu 9, naznačeno time što se protutijelo ili njegov fragment koji se veže na antigen, nukleinska kiselina, vektor, stanica, ili farmaceutski pripravak primjenjuje u kombinaciji s inhibitorom kontrolne točke.
11. Upotreba protutijela, ili njegovog fragmenta koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3 u in vitro dijagnostici infekcije Zika virusom.
12. Upotreba protutijela ili njegovog fragmenta koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3 za in vitro praćenje kvalitete anti-Zika cjepiva provjerom sadrži li antigen navedenog cjepiva specifični epitop u ispravnoj konformaciji.
13. Komplet dijelova koji sadrži najmanje jedno protutijelo, ili njegov fragment koji veže antigen, prema bilo kojem od zahtjeva 1 do 3, najmanje jednu nukleinsku kiselinu prema zahtjevu 5, najmanje jedan vektor prema zahtjevu 6, najmanje jednu stanicu prema zahtjevu 7, ili najmanje jedan farmaceutski pripravak prema zahtjevu 8, i sredstva za primjenu protutijela ili njegovog fragmenta koji veže antigen, nukleinske kiseline, vektora, stanice ili farmaceutskog pripravka.
HRP20231196TT 2016-07-13 2017-07-12 Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba HRP20231196T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/066684 WO2018010789A1 (en) 2016-07-13 2016-07-13 Novel antibodies specifically binding to zika virus epitopes and uses thereof
EP17742985.9A EP3484915B1 (en) 2016-07-13 2017-07-12 Novel antibodies specifically binding to zika virus epitopes and uses thereof
PCT/EP2017/067581 WO2018011283A1 (en) 2016-07-13 2017-07-12 Novel antibodies specifically binding to zika virus epitopes and uses thereof

Publications (1)

Publication Number Publication Date
HRP20231196T1 true HRP20231196T1 (hr) 2024-01-19

Family

ID=56413654

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231196TT HRP20231196T1 (hr) 2016-07-13 2017-07-12 Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba

Country Status (31)

Country Link
US (3) US11117954B2 (hr)
EP (2) EP4342911A1 (hr)
JP (2) JP7252888B2 (hr)
KR (1) KR102595764B1 (hr)
CN (2) CN116199775A (hr)
AU (1) AU2017297757B2 (hr)
BR (1) BR112018074456A2 (hr)
CA (1) CA3024374A1 (hr)
CL (2) CL2019000067A1 (hr)
CO (1) CO2019001111A2 (hr)
CR (1) CR20190066A (hr)
DK (1) DK3484915T5 (hr)
DO (2) DOP2019000006A (hr)
EA (1) EA201990243A1 (hr)
EC (1) ECSP19009170A (hr)
ES (1) ES2959883T3 (hr)
FI (1) FI3484915T3 (hr)
HR (1) HRP20231196T1 (hr)
HU (1) HUE063272T2 (hr)
IL (1) IL262710B2 (hr)
LT (1) LT3484915T (hr)
MX (1) MX2019000526A (hr)
MY (1) MY190553A (hr)
PE (1) PE20190398A1 (hr)
PH (1) PH12018502348A1 (hr)
PL (1) PL3484915T3 (hr)
SG (1) SG11201809879WA (hr)
SI (1) SI3484915T1 (hr)
UA (1) UA126381C2 (hr)
WO (2) WO2018010789A1 (hr)
ZA (1) ZA201807467B (hr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11946017B2 (en) 2016-07-13 2024-04-02 Evonik Operations Gmbh Method of separating lipids from a lysed lipids containing biomass
MY191894A (en) 2016-10-13 2022-07-18 Nat Univ Singapore Antibodies that bind zika virus envelope protein and uses thereof
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EP3527664A1 (en) 2018-02-15 2019-08-21 Evonik Degussa GmbH Method of isolating lipids from a lipids containing biomass
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
CA3098373A1 (en) 2018-04-24 2019-10-31 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination
RU2760575C1 (ru) 2018-05-15 2021-11-29 Эвоник Оперейшнс Гмбх Способ выделения липидов из содержащей липиды биомассы с помощью гидрофобного диоксида кремния
US11976253B2 (en) 2018-05-15 2024-05-07 Evonik Operations Gmbh Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion
WO2020061159A1 (en) * 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
WO2020092564A1 (en) * 2018-10-31 2020-05-07 Icahn School Of Medicine At Mount Sinai Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
JP7463366B2 (ja) * 2018-11-20 2024-04-08 タケダ ワクチン,インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
WO2020245663A1 (en) * 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
US20230085393A1 (en) * 2019-11-19 2023-03-16 Vanderbilt University Human antibodies that neutralize zika virus and methods of use therefor
CN111100201B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体
CN111138534B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 寨卡病毒囊膜蛋白的鼠源单克隆抗体
JP7471555B2 (ja) * 2020-02-20 2024-04-22 国立感染症研究所長 フラビウイルス交差中和抗体及び医薬組成物
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン,インコーポレイテッド ジカウイルス特異的抗体の検出方法
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2022001803A1 (zh) * 2020-06-28 2022-01-06 神州细胞工程有限公司 一种降低病毒ade效应的方法
EP4313102A2 (en) * 2021-04-01 2024-02-07 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
CN112921124B (zh) * 2021-04-08 2021-09-28 广东创晟控股集团有限公司 一种快速检测病毒的试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CN101802197A (zh) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC(ScFc)区、包含其的结合多肽及与其相关的方法
DK2350128T3 (da) 2008-10-22 2014-12-01 Inst Research In Biomedicine Fremgangsmåder til fremstilling af antistoffer fra plasmaceller
CA2901358C (en) * 2013-03-15 2022-07-26 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
JP2019511221A (ja) 2016-03-11 2019-04-25 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 弱毒化された生ジカウイルスワクチン
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
PT3658557T (pt) 2017-07-28 2024-09-11 Nimbus Lakshmi Inc Inibidores de tyk2 e usos dos mesmos

Also Published As

Publication number Publication date
MY190553A (en) 2022-04-27
MX2019000526A (es) 2019-05-02
SI3484915T1 (sl) 2024-02-29
EP3484915A1 (en) 2019-05-22
IL262710A (en) 2018-12-31
SG11201809879WA (en) 2018-12-28
WO2018010789A1 (en) 2018-01-18
CL2021002994A1 (es) 2022-09-09
CN109563157A (zh) 2019-04-02
HUE063272T2 (hu) 2024-01-28
ZA201807467B (en) 2024-04-24
EP3484915B1 (en) 2023-08-16
AU2017297757A1 (en) 2018-11-22
DOP2019000006A (es) 2019-03-31
FI3484915T3 (fi) 2023-11-15
AU2017297757B2 (en) 2024-06-13
PH12018502348A1 (en) 2019-03-25
IL262710B2 (en) 2024-05-01
JP2019533425A (ja) 2019-11-21
JP2023062036A (ja) 2023-05-02
ES2959883T3 (es) 2024-02-28
JP7252888B2 (ja) 2023-04-05
CN109563157B (zh) 2023-01-17
EA201990243A1 (ru) 2019-07-31
US11117954B2 (en) 2021-09-14
ECSP19009170A (es) 2019-02-28
PE20190398A1 (es) 2019-03-13
CR20190066A (es) 2019-09-10
KR20190027382A (ko) 2019-03-14
KR102595764B1 (ko) 2023-10-30
IL262710B1 (en) 2024-01-01
DOP2021000026A (es) 2021-07-30
WO2018011283A1 (en) 2018-01-18
US20210363227A1 (en) 2021-11-25
CO2019001111A2 (es) 2019-08-20
LT3484915T (lt) 2023-10-10
PL3484915T3 (pl) 2024-03-25
US11912757B2 (en) 2024-02-27
CA3024374A1 (en) 2018-01-18
UA126381C2 (uk) 2022-09-28
CN116199775A (zh) 2023-06-02
US20190256582A1 (en) 2019-08-22
DK3484915T5 (da) 2024-09-02
CL2019000067A1 (es) 2019-07-26
US20210355198A1 (en) 2021-11-18
DK3484915T3 (da) 2023-10-09
BR112018074456A2 (pt) 2019-03-19
EP4342911A1 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
HRP20231196T1 (hr) Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
JP2018535650A5 (hr)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2018521638A5 (hr)
JP2020500538A5 (hr)
JP2011528902A5 (hr)
JP2012504955A5 (hr)
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
JP2011528901A5 (hr)
CN110642944B (zh) 一种中和人感染h7n9甲型流感病毒的抗体及其用途
RU2016100892A (ru) Антитела против tweakr и их применение
CN107667114B (zh) 中和抗流感结合分子及其用途
US11730813B2 (en) Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
US10654915B2 (en) Antibodies useful in passive influenza immunization
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2010516229A5 (hr)
RU2012112829A (ru) Анти-gitr-антитела
JP2023071956A5 (hr)
RU2014145536A (ru) Антитело против adamts-5, его производные и их применение
RU2017128512A (ru) Антитела к теофиллину и способы их применения
RU2018115246A (ru) Композиции антител к вич и способы их применения
JP2012510802A (ja) 完全ヒトインフルエンザm2特異的抗体